A Phase 4 interventional study of In situ cutaneous microdevice and Triamcinolone in Psoriasis and Atopic Dermatitis, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Device feasibility
How we know · 36 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Psoriasis by University of California, San Francisco — 6 open to participants now, 6 under way, none of them phase 3. Psoriasis · University of California, San Francisco.
Among the 18 studies in Psoriasis by University of California, San Francisco, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 4, and was the 16th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →6 of the 18 studies in Psoriasis by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18–75
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 18 across the 17 interventional studies, 24 across the 1 observational. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Psoriasis by University of California, San Francisco, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Inclusion Criteria:
> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral pills or intrauterine device for at least 30 days)
Exclusion Criteria: None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Device: In situ cutaneous microdevice · Drug: Triamcinolone · Drug: 5-Fluorouracil · Drug: Calcipotriene · Drug: Tapinarof · Drug: Crisaborole · Drug: Tacrolimus · Drug: Adalimumab · Drug: Etanercept · Drug: Certolizumab · Drug: Infliximab · Drug: Secukinumab · Drug: Ixekizumab · Drug: Apremilast · Drug: Risankizumab · Drug: Ustekinumab · Drug: Hydroxychloroquine · Drug: Methotrexate · Drug: Mycophenolate · Drug: Azathioprine · Drug: Chloroquine · Drug: Cyclosporine · Drug: Tofacitinib · Drug: Deucravacitinib · Drug: Dupilumab · Drug: Tralokinumab · Drug: Guselkumab · Drug: Tildrakizumab · Drug: Baractinib · Drug: Abrocitinib · Drug: Upadacitinib · Drug: Lebrikizumab · Drug: Nemolizumab · Drug: Ruxolitinib · Drug: Bimekizumab · Drug: Roflumilast
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.
Triamcinolone
5-fluorouracil
Calcipotriene
Tapinarof
Crisaborole
Tacrolimus
Adalimumab
Etanercept
Certolizumab
Infliximab
Secukinumab
Ixekizumab
Apremilast
Risankizumab
Ustekinumab
Hydroxychloroquine
Methotrexate
Mycophenolate
Azathioprine
Chloroquine
Cyclosporine
Tofacitinib
Deucravacitinib
Dupilumab
Tralokinumab
Guselkumab
Tildrakizumab
Baractinib
Abrocitinib
Upadacitinib
Lebrikizumab
Nemolizumab
Ruxolitinib
Bimekizumab
Roflumilast
Number of participants with adverse events
The safety of microdevice placement and removal will be based on assessment of adverse events.
Time frame: 1 year
Proportion of retrieved devices with assessable tissue
The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.
Time frame: 1 year
Change in local skin inflammation (molecular assays)
Feasibility of utilizing quantitative histopathologic assessment and/or transcriptional profiling to determine whether there is local change in lesional rash-affected skin with clinically relevant skin inflammation treating agents.
Time frame: 1 year
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Aug 2026; primary completion for Jun 2030, 46 months later.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 46 months is above that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Triamcinolone · Fluorouracil · Calcipotriene · Tapinarof · Crisaborole · Tacrolimus · Adalimumab · Etanercept · Certolizumab Pegol · Infliximab · Secukinumab · Ixekizumab · Apremilast · Risankizumab · Ustekinumab · Hydroxychloroquine · Methotrexate · Mycophenolic Acid · Azathioprine · Chloroquine · Cyclosporine · Tofacitinib · Deucravacitinib · Dupilumab · Tralokinumab · Guselkumab · Tildrakizumab · Abrocitinib · Upadacitinib · Lebrikizumab · Nemolizumab · Ruxolitinib · Bimekizumab · Roflumilast
University of California, San Francisco →